



Geron to Present at the H.C. Wainwright BioConnect Conference

1/4/2022

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference.

The pre-recorded company presentation will be available beginning at 7 a.m. ET / 4 a.m. PT on January 10, 2022 using the following link: <https://journey.ct.events/view/0a8abdcd-614c-42a5-86d4-1b5902e19d32> and will also be available on the Investor Relations section of Geron's website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMPactMF in refractory myelofibrosis. For more information about Geron, visit www.geron.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220104006038/en/): <https://www.businesswire.com/news/home/20220104006038/en/>

Olivia Bloom
Chief Financial Officer
investor@geron.com
media@geron.com

Source: Geron Corporation